benzyl thiocyanate: increases activities of anhydrotetracycline oxygenase
ID Source | ID |
---|---|
PubMed CID | 18170 |
CHEMBL ID | 2251721 |
CHEBI ID | 16017 |
SCHEMBL ID | 129196 |
MeSH ID | M0106682 |
Synonym |
---|
LS-13408 |
nsc-130266 |
nsc130266 |
benzylthiocyanate |
solvat 14 |
.alpha.-thiocyanatotoluene |
tropeolin |
nsc1729 |
toluene, .alpha.-thiocyanato- |
wln: ncs1r |
nsc-1729 |
thiocyanic acid, benzyl ester |
thiocyanic acid, phenylmethyl ester |
alpha-thiocyanatotoluene |
CHEBI:16017 , |
thiocyanic acid benzyl ester |
phenylmethyl thiocyanate |
ccris 3085 |
benzyl-thiocyanate |
einecs 221-144-2 |
benzylrhodonid |
brn 1859726 |
toluene, alpha-thiocyanato- |
ai3-08887 |
nsc 1729 |
nsc 130266 |
inchi=1/c8h7ns/c9-7-10-6-8-4-2-1-3-5-8/h1-5h,6h |
3012-37-1 |
C02660 |
benzyl thiocyanate |
AJ-087/40225997 |
STK331791 |
benzyl thiocyanate, >=95.0% (gc) |
AKOS005142996 |
T0198 |
NCGC00248493-01 |
thiocyanato-methyl-benzene |
4-06-00-02680 (beilstein handbook reference) |
yx8tao9o90 , |
unii-yx8tao9o90 |
tox21_200015 |
NCGC00257569-01 |
dtxcid90156 |
dtxsid5020156 , |
cas-3012-37-1 |
A820216 |
(benzylsulfanyl)carbonitrile |
SCHEMBL129196 |
CHEMBL2251721 |
benzyl thiocyanate [who-dd] |
bdbm50073737 |
mfcd00001832 |
phenylmethyl thiocyanate, 9ci |
alpha-thiocyanato-toluene |
toluene, alpha -thiocyanato- |
alpha -thiocyanatotoluene |
benzyl rhodanide |
J-017789 |
(thiocyanatomethyl)benzene |
Q18341008 |
E78897 |
EN300-127576 |
Class | Description |
---|---|
thiocyanates | Esters of thiocyanic acid with general formula RSC#N. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
aromatic glucosinolate activation | 1 | 9 |
aromatic glucosinolate activation | 1 | 11 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 63.5190 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.2247 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 68.8687 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 52.8959 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID743053 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 68.8687 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 48.7553 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 43.4532 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.8938 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 9.8095 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 58.4315 | 0.0578 | 21.1097 | 61.2679 | AID1159528 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 72.9495 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 27.4171 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 77.2720 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 77.2720 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Macrophage migration inhibitory factor | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0380 | 3.0910 | 9.8000 | AID1198788 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1198788 | Inhibition of macrophage migration inhibitory factor tautomerase activity in human Jurkat T cells using L-dopachrome methyl ester as substrate incubated for 30 mins prior to substrate addition measured for 2 mins by spectrophotometric analysis | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Multiple binding modes of isothiocyanates that inhibit macrophage migration inhibitory factor. |
AID1198787 | Inhibition of human recombinant macrophage migration inhibitory factor tautomerase activity expressed in Escherichia coli DH5alpha using L-dopachrome methyl ester as substrate incubated for 5 mins prior to substrate addition measured for 2 mins by spectro | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Multiple binding modes of isothiocyanates that inhibit macrophage migration inhibitory factor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 12 (52.17) | 18.7374 |
1990's | 7 (30.43) | 18.2507 |
2000's | 2 (8.70) | 29.6817 |
2010's | 2 (8.70) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.72) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (4.17%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 23 (95.83%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |